C.Q.Pharmaceutical Holding

C.Q. Pharmaceutical Holding Co., Ltd. is a large state-controlled modern pharmaceutical distribution enterprise serving the entire pharmaceutical industry chain. It is also engaged in pharmaceutical research and development, medical device production, and investment participation in pharmaceutical manufacturing. The company is listed on the Shenzhen Stock Exchange, with the stock code: 000950, and a registered capital of 1.743 billion yuan. The main operating entity under the listed company is Chongqing Pharmaceutical (Group) Co., Ltd., whose predecessor was the Southwest Branch of China Pharmaceutical Corporation established in 1950. It is a designated reserve unit for medicines and medical devices at both central and local levels, and one of only three national wholesale enterprises in China authorized to distribute anesthetic drugs and psychotropic substances of the first category. Its scale and market coverage rank among the top in western China. In 2021, the company achieved revenue of 62.521 billion yuan and total profits of 1.58 billion yuan, representing year-on-year growth of 38.26% and 14.97%, respectively, and paid taxes of 1.38 billion yuan, ranking it among the top five in China's pharmaceutical commerce sector. The company owns more than 200 subsidiaries at all levels and employs over 14,000 people, with operations spanning 27 provinces, municipalities, and autonomous regions across China.The company’s core pharmaceutical business covers hospital direct sales, commercial wholesale, retail chains, terminal delivery, warehousing and logistics, and supply chain value-added services for medicines, medical devices, Chinese herbal decoctions, and health products. Its marketing network spans all 31 provinces, municipalities, and autonomous regions in China. In the 2019 new round of healthcare reform "4+7" volume-based procurement initiative, the company took the lead, laying a solid foundation for the expanded procurement efforts in 2020. The company has built a leading "pharmaceuticals + internet" platform in China's pharmaceutical commerce sector, engaging in B2B, B2C, O2O, and other pharmaceutical e-commerce businesses. Supported by information technologies such as the internet, the Internet of Things, artificial intelligence, big data applications, and mobile terminals, it provides auxiliary medical services including chronic disease management, electronic prescription circulation, off-site pharmaceutical affairs management, and remote diagnosis and treatment. The company owns well-known national brands "Heping Pharmacy" and "Xinjiankang Pharmacy," which operate more than 800 stores across sixteen provinces, municipalities, and autonomous regions, including Sichuan, Chongqing, and Guizhou. It also operates Heping Pharmacy’s online mall and engages in in-hospital self-pay pharmacies, DTP specialty drug direct delivery, and hospital infusion centers. The company possesses a leading modern pharmaceutical logistics distribution center in China, with multiple distribution centers set up domestically and a total warehouse area of over 492,000 square meters. By utilizing intelligent logistics technology within hospitals, the company collaborates with large general hospitals to implement forward warehouse placement, complementing small and medium-sized hospitals and regional medical centers to establish central warehouses for centralized distribution.In pharmaceutical R&D, the company adheres to innovation as its development philosophy and has established a comprehensive new drug R&D system aligned with its strategic planning. Adopting international standards, it invests in, screens, cultivates, and submits high-value-added chemical drugs, traditional Chinese medicines, biologics, and medical devices that fit within its development areas. At the same time, it fully leverages its existing pharmaceutical commerce channels, retail networks, and medical institution advantages to drive the marketing and promotion of new products, achieving industrial synergy.Currently, the company is transforming from a traditional distribution business to a modern pharmaceutical commerce model integrated with "internet + pharmaceuticals," fostering strong sustainable competitive capabilities. Upholding the corporate spirit of "dedication to pharmaceuticals, pursuit of excellence," and adhering to the core values of "responsibility, humanism, harmony, and gratitude," the company seizes significant opportunities in the development of the pharmaceutical and health industry, persists in innovative development, and is committed to building a world-class pharmaceutical and health industry group with domestic leadership and international renown.